HomeCLLS • NASDAQ
add
Cellectis SA
Previous close
$2.00
Day range
$1.95 - $2.04
Year range
$0.96 - $3.77
Market cap
147.13M USD
Avg Volume
21.58K
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Jun 2024info | Y/Y change |
|---|---|---|
Revenue | 9.50M | 374.91% |
Operating expense | 26.71M | 4.26% |
Net income | -25.27M | -115.85% |
Net profit margin | -265.92 | 54.55% |
Earnings per share | -0.27 | -80.00% |
EBITDA | -14.47M | 31.63% |
Effective tax rate | 0.76% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Jun 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 149.04M | 76.62% |
Total assets | 407.15M | 78.83% |
Total liabilities | 258.54M | 97.18% |
Total equity | 148.61M | — |
Shares outstanding | 100.09M | — |
Price to book | 1.35 | — |
Return on assets | -11.30% | — |
Return on capital | -19.88% | — |
Cash Flow
Net change in cash
| (USD) | Jun 2024info | Y/Y change |
|---|---|---|
Net income | -25.27M | -115.85% |
Cash from operations | 52.18M | 374.01% |
Cash from investing | -106.43M | -5,852.40% |
Cash from financing | 78.51M | 296.18% |
Net change in cash | 26.07M | 2,303.80% |
Free cash flow | -27.61M | -451.63% |
About
Cellectis is a French biopharmaceutical company. It develops genome-edited chimeric antigen receptor T-cell technologies for cancer immunotherapy. It has offices in Paris, New York City, and Raleigh, North Carolina. Wikipedia
Founded
1999
Website
Employees
219
